Please read SSC’s statement below regarding the final CADTH recommendation for Vraylar and to learn more about how we will be advocating for publicly funded access to this important medication. In the coming weeks, we will be going to the media to build awareness around this issue, so please stay tuned for more information.
–
The voices of both those with lived/living experience and their families possess the capacity for positive change, so if you or a loved one is interested in sharing your personal experience of living with the negative symptoms of schizophrenia, please reach out to us at [email protected]
Statement from SSC regarding negative CADTH reimbursement recommendation for Vraylar (Cariprazine)
The Schizophrenia Society of Canada (SSC) advocates on behalf of individuals and families affected by early psychosis and schizophrenia which is an important part of our mission: Build a Canada where people living with early psychosis and schizophrenia reach their potential.
As a part of our commitment to ensuring that persons with enduring mental health problems have the right to appropriate care, treatment, rehabilitation, and recovery within the least restrictive environment, we are currently advocating for publicly funded access to Vraylar (Cariprazine) across Canada. This treatment fills an expressed unmet need for people living with schizophrenia, their family members, and physicians as a therapeutic option to address negative symptoms and reliably improve psychosocial functioning to support recovery and reintegration.
Medications are crucial to symptom control within the schizophrenia treatment process; however, no single, simple course of treatment exists and access to treatment options is critical. Prior to Vraylar’s approval in Canada in April 2022, medications had only addressed positive symptoms of schizophrenia without adequately treating negative or cognitive symptoms, or reliably improving psychosocial function.
On August 26, 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued a final recommendation that Vraylar (cariprazine) should not be publicly reimbursed for the